Compare LYRA & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LYRA | BGMS |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 5.0M |
| IPO Year | 2020 | N/A |
| Metric | LYRA | BGMS |
|---|---|---|
| Price | $1.32 | $0.83 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 64.2K | 17.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,534,000.00 | N/A |
| Revenue This Year | N/A | $137.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.08 | $0.74 |
| 52 Week High | $37.50 | $6.70 |
| Indicator | LYRA | BGMS |
|---|---|---|
| Relative Strength Index (RSI) | 40.29 | 36.87 |
| Support Level | $1.21 | $0.74 |
| Resistance Level | $1.52 | $1.12 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 72.12 | 54.96 |
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.